Pediatric ID News

Guidelines for ear infections in young children may lead to unnecessary tympanostomy tube placement, according to a study published in Pediatrics.

The FDA will review a biologics license application for nirsevimab for the prevention of respiratory syncytial virus in newborns and infants, according to Sanofi and AstraZeneca, which are developing the monoclonal antibody.

The FDA has accepted for priority review a supplemental biologics license application for Pfizer’s 20-valent pneumococcal conjugate vaccine for use in infants and children aged 6 weeks to 17 years, Pfizer announced.

The XBB.1.5 omicron subvariant has evolved to become the most transmissible SARS-CoV-2 subvariant yet, rapidly replacing other variants, although its ultimate impact on the pandemic is unclear, according to experts.

A study found no reported serious adverse events among children who received a COVID-19 vaccine after recovering from multisystem inflammatory syndrome in children, or MIS-C, according to results published in JAMA Network Open.

Updated COVID-19 shots, including bivalent boosters, dominated vaccine news in 2022, but good news also came for vaccines against malaria, Ebola and cancer.

2022 was an important year in pediatrics — gun violence is now the leading cause of death among children, and findings suggest that kids are missing out on routine immunizations, setting the stage for outbreaks of preventable illnesses.

Starting Jan. 5, the United States will require inbound air travelers from China to present a negative COVID-19 test or documentation of recovery from COVID-19 when boarding their flight, the CDC announced.

Mpox spread around the globe in 2022, popping up in 110 countries — including 103 that had not historically reported the disease, according to CDC tracking.

As the COVID-19 pandemic enters its 4th year, its effect on children continues to be widely studied. We compiled a list of pediatric COVID-19 stories reported over the course of the past year.